NCT05333003View on ClinicalTrials.gov

Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity

NARecruitingINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

May 25, 2022

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions
Schizophrenia Spectrum Disorders
Interventions
DRUG

Semaglutide

The semaglutide dose will start with 0.25 mg/week, and slowly increased every four weeks as tolerated up to a maximal dose of 2 mg/week

OTHER

Placebo

Placebo will be provided to participants

Trial Locations (1)

M6J 1H4

RECRUITING

Centre for Addiction and Mental Health, Toronto

All Listed Sponsors
lead

Centre for Addiction and Mental Health

OTHER